Milestone Pharmaceuticals Inc. Amortization of Debt Issuance Costs and Discounts
Milestone Pharmaceuticals Inc. (MIST) reported Amortization of Debt Issuance Costs and Discounts of $235.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $118.00K, a 11.32% increase year-over-year.
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $117.00K, a 14.71% increase year-over-year.
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $115.00K, a 18.56% increase year-over-year.
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $109.00K, a 14.74% increase year-over-year.
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for fiscal 2025 was $432.00K, a 16.76% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $370.00K, a 51.64% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $244.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $235.00K 10-Q · filed 2026-08-12 | $350.00K derived: sum of 3 quarters · filed 2026-08-12 | $459.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $117.00K 10-Q · filed 2026-05-13 | $232.00K derived: sum of 2 quarters · filed 2026-05-13 | $341.00K derived: sum of 3 quarters · filed 2026-05-13 | $447.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $224.00K derived: sum of 2 quarters · filed 2026-03-20 | $330.00K derived: sum of 3 quarters · filed 2026-08-12 | $432.00K 10-K · filed 2026-03-20 |
| 2025-09-30 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $215.00K derived: sum of 2 quarters · filed 2026-08-12 | $317.00K 10-Q · filed 2025-11-12 | $414.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $208.00K 10-Q · filed 2026-08-12 | $305.00K derived: sum of 3 quarters · filed 2026-08-12 | $400.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $102.00K 10-Q · filed 2026-05-13 | $199.00K derived: sum of 2 quarters · filed 2026-05-13 | $294.00K derived: sum of 3 quarters · filed 2026-05-13 | $385.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $192.00K derived: sum of 2 quarters · filed 2026-03-20 | $283.00K derived: sum of 3 quarters · filed 2026-03-20 | $370.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $186.00K derived: sum of 2 quarters · filed 2025-11-12 | $273.00K 10-Q · filed 2025-11-12 | $357.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $178.00K 10-Q · filed 2025-08-12 | $262.00K derived: sum of 3 quarters · filed 2025-08-12 | $342.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $87.00K 10-Q · filed 2025-05-14 | $171.00K derived: sum of 2 quarters · filed 2025-05-14 | $251.00K derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $164.00K derived: sum of 2 quarters · filed 2025-03-13 | $244.00K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $160.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $80.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |